LEIDEN, Netherlands and CAMBRIDGE, Mass.,
Presentation at the 3rd Annual
A presentation will be delivered by
|Presentation Title:||Antisense Oligonucleotides for Inherited Retinal Diseases|
|Presentation Time:||Wednesday, November 20 at 1:20-2:00 p.m. GMT|
Presentation at the 1st RNA Editing Summit
During the 1st RNA Editing Summit to be held on
|Presentation Title:||Translating RNA Editing to Our Clinical Development Pipelines|
|Presentation Time:||Wednesday, November 20 at 9:40-10:10 a.m. EST|
This presentation will highlight ProQR’s proprietary Axiomer® platform, a fully owned and in house developed RNA platform with broad applicability. ProQR is accelerating this platform for precision medicine in the retina with oligonucleotide therapeutics.
About Axiomer® platform technology
ProQR is pioneering a next-generation RNA technology called Axiomer®, which could potentially yield a new class of medicines for genetic diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells. The Axiomer® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G).
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include those relating to our participation at the 3rd Annual
LifeSci Public Relations
T: +1 646 876 4933
Source: ProQR Therapeutics N.V.